| Julie Dellerba, APRN | |
|
20 13th St W, Havre, MT 59501-5215 | |
| (406) 262-1419 | |
| Not Available |
| Full Name | Julie Dellerba |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 20 13th St W, Havre, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538530027 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 101136 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Montana Hospital | Havre, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Montana Hospital | 2264343912 | 37 |
News Archive
Nearly 90 percent of the 700,000 strokes that affect U.S. patients each year are caused by a blockage of blood vessels supplying the brain, known as ischemic stroke.
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 6 days ago
| Entity Name | Northern Montana Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427059070 PECOS PAC ID: 2264343912 Enrollment ID: O20031229000278 |
News Archive
Nearly 90 percent of the 700,000 strokes that affect U.S. patients each year are caused by a blockage of blood vessels supplying the brain, known as ischemic stroke.
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Dellerba, APRN Po Box 1231, Havre, MT 59501-1231 Ph: () - | Julie Dellerba, APRN 20 13th St W, Havre, MT 59501-5215 Ph: (406) 262-1419 |
News Archive
Nearly 90 percent of the 700,000 strokes that affect U.S. patients each year are caused by a blockage of blood vessels supplying the brain, known as ischemic stroke.
Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 6 days ago
Mrs. Carol Ann Milne, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 110 13th St, Havre, MT 59501 Phone: 406-265-4541 Fax: 406-265-2148 | |
Kathryn Elaine Olson, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 521 4th St, Havre, MT 59501 Phone: 406-395-4305 Fax: 406-395-5643 | |
Kayla Marie Stoner, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1058 Cleveland Ave, Havre, MT 59501 Phone: 406-262-4879 | |
Mrs. Jennifer Anne Durward, APRN, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 311 3rd St, Havre, MT 59501 Phone: 406-945-9019 Fax: 406-430-0176 | |
Rosaula Nymphadacumos Lapine, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 521 4th St, Havre, MT 59501 Phone: 406-395-4305 Fax: 406-395-5643 | |
Dr. Courtney Lee Funderburk, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 20 13th St W, Havre, MT 59501 Phone: 406-265-7831 Fax: 406-262-1636 | |
Connie S Reichelt, APRN, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 110 13th St, Havre, MT 59501 Phone: 406-265-4541 Fax: 406-265-2481 |